We’re delighted to announce the launch of our TruSight™ Oncology Comprehensive (EU), our newest CE-marked IVD test for Comprehensive Genomic Profiling (CGP). Pathologists and Oncologists can now benefit from end-to-end solution that:

  • Detects majority of approved and emerging therapy biomarkers across multiple solid tumour types, including those in ESMO recommendations, EMA drug labels and local clinical trials
  • Maximizes ability to find actionable alterations, that can inform therapy regimens for cancer patients
  • Consolidates multiple individual iterative tests into a single CGP workflow, saving biopsy sample and precious time, so oncologists can make timely decisions for their patients
  • Has been validated by Illumina, is kitted and IVD labelled, so your organization can internalize the test and offer through your institutions

With the high interest post our IVD roadmap update during ESMO, we’re hosting a VIP launch webinar event to introduce the benefits of the test, how Illumina supports customers with implementation, and our ongoing efforts towards market accessibly.

Find out more about our cutting edge, IVD solution, be part of the conversation, join us by registering to attend this event.

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
29 Mar 2022
5:00 PM
Watch Now